MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenon

BACKGROUND: MET amplification appears to be a predictive biomarker for MET inhibition. Prior studies reported a MET amplification rate of 9–18% in metastatic colorectal cancer (mCRC) but do not differentiate increased gene copy numbers due to chromosomal level aberrations from focal gene amplificati...

Descripción completa

Detalles Bibliográficos
Autores principales: Raghav, Kanwal, Morris, Van, Tang, Chad, Morelli, Pia, Amin, Hesham M., Chen, Ken, Manyam, Ganiraju C., Broom, Bradley, Overman, Michael J., Shaw, Kenna, Meric-Bernstam, Funda, Maru, Dipen, Menter, David, Ellis, Lee M., Eng, Cathy, Hong, David, Kopetz, Scott
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342368/
https://www.ncbi.nlm.nih.gov/pubmed/27421137
http://dx.doi.org/10.18632/oncotarget.10559

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342368/
https://www.ncbi.nlm.nih.gov/pubmed/27421137
http://dx.doi.org/10.18632/oncotarget.10559

Ejemplares similares